Re: "BMY-ZGEN post-mortem:" Since NVS sold their shares at 9.75 I think any further discussion of "fair value" is moot. (Though I do agree agree that the BMS milestone payments were obviously at risk. To borrow Wallstarb's term, they were "bio-bucks".)